Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung has maintained an Equal-Weight rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and raised the price target from $20 to $21.
July 11, 2023 | 12:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on ACADIA Pharmaceuticals and raised the price target from $20 to $21.
The news of Morgan Stanley maintaining an Equal-Weight rating on ACADIA Pharmaceuticals and raising the price target from $20 to $21 is directly related to ACADIA Pharmaceuticals. This could potentially lead to an increase in the stock price in the short term as it indicates a positive outlook from the analyst.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100